Novavax Inc. stock underperforms Wednesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Wednesday when compared to competitors | news.google.com • |
Novavax, Inc. (NASDAQ:NVAX) is Shah Capital Management's 2nd Largest Position | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-08 | 2024-06 | 1.82 | 0.99 | -0.83 | -45.60% |
2024-05-10 | 2024-03 | -1.04 | -1.05 | -0.01 | -0.96% |
2024-02-28 | 2023-12 | -0.49 | -1.44 | -0.95 | -193.88% |
2023-11-09 | 2023-09 | -1.82 | -1.26 | 0.56 | 30.77% |
2023-08-08 | 2023-06 | -1.24 | 0.58 | 1.82 | 146.77% |
2023-05-09 | 2023-03 | -3.38 | -3.41 | -0.03 | -0.89% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-08 | B. Riley Securities | Upgrade | Neutral | Buy |
2023-05-09 | HC Wainwright & Co. | Upgrade | Buy | |
2023-02-28 | B. Riley Securities | Downgrade | Buy | Neutral |
2023-02-12 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-01 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-06-11 | ALTON GREGG H | Director | 10.47K | Conversion of Exercise of derivative security |
2024-06-11 | DOUGLAS RICHARD H | Director | 43.92K | Conversion of Exercise of derivative security |
2024-06-16 | DUBOVSKY FILIP | Officer | 66.61K | Sale |
2024-08-15 | KELLY JAMES PATRICK | Chief Financial Officer | 14.43K | Conversion of Exercise of derivative security |
2024-06-11 | KING RACHEL K | Director | 18.92K | Conversion of Exercise of derivative security |
2024-06-11 | MCGLYNN MARGARET G | Director | 10.47K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | State Street Corporation | 11.68M | 86.78M | 12.37% |
2023-06-29 | Vanguard Group Inc | 10.57M | 78.55M | 11.20% |
2023-06-29 | Blackrock Inc. | 6.99M | 51.97M | 7.41% |
2023-09-29 | Shah Capital Management | 6.33M | 45.83M | 6.71% |
2023-06-29 | Bank of America Corporation | 2.18M | 16.23M | 2.31% |
2023-06-29 | Morgan Stanley | 2.08M | 15.46M | 2.20% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 9.38M | 75.07M | 9.94% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.64M | 19.60M | 2.79% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.23M | 16.56M | 2.36% |
2023-08-30 | iShares Russell 2000 ETF | 2.01M | 16.10M | 2.13% |
2023-06-29 | Vanguard Small-Cap Growth Index Fund | 1.28M | 9.48M | 1.35% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.21M | 8.98M | 1.28% |
Split | Date |
---|---|
1 : 20 | 2019-05-10 |
-
@ N Shah
-
$NVAX HOP IN $ATER BEFORE IT BREAKS OUT TO THE MOON. #1 RANKED & TRENDING FOR SQUEEZE BREAKOUT. DONT WAKE UP MONDAY REGRETTING NOT GETTING IN BEFORE CLOSE. $ATER
-
$NVAX EVERYONE HOP ON THE $ATER TRAIN BEFORE IT BLOWS! RANKED #1 FOR AN IMMINENT SQUEEZE SOON!
-
Good opportunity to add more position of NVAX for long term. COVID vaccine will be with us like flu shot that we have to take every year. NVAX is more economical than PFE n MRNA to make and easier to transport and manage thus it is more desirable to countries that can’t afford/manage PFE n MRNA. So NVAX is a better choice for long term investment.
-
$NVAX where are you Stan? Can you show some leadership to this company??
-
Produced antigens are kept frozen until finish and fill and almost unlimited shelve life.
-
Well all other countries are fighting for PFE n MRNA if they can’t get them then they’d to settle for NVAX n JNJ.
-
Indian govt wants PFE n MRNA since they are approved n used on hundred millions in the US. They don’t want to take any chances on other vaccines. Can’t blame them.
-
Green by EOD
-
Diversify NVAX w/ MRNA n BNTX, if you don’t have the stomach to pick only one
-
Creeping back to green line. Last chance for those who want to add
-
Healthy pullback to get ready for taking off again.
-
Here comes the typical NVAX tank ride
-
-
I see it going to to $248.1 and below. Get ready to load at a cheaper price.
-
I see it going to to $248.1 and below
-
Come on,I want to see red again so I can buy at a better price.
-
NVAX $2000 will happen
Breaking News, Thursday, Munich: Novavax expected for infants, headline: “Pediatricians expect corona vaccine for infants”
“He expects a lot from the vaccine from the US manufacturer Novavax. The drug is not an mRNA vaccine, but as a so-called conjugate vaccine it is similar to many conventional children's vaccines with which one already has billions of experience.
"The vaccine has not yet been approved, but the recently published study results look very good," said Hoffmann.” Link in comments. -
Novavax NVAX can be another potential winner in the COVID-19 vaccine race. Although the company’s COVID-19 vaccine is yet to receive an authorization/approval, the vaccine demonstrated robust efficacy in a late-stage study. In June 2021, Novavax announced data from the phase III PREVENT-19 study, which evaluated NVX-CoV2373 in the United States and Mexico. The study met its primary endpoint by demonstrating an overall vaccine efficacy of 90.4%. The vaccine also provided 100% protection against moderate and severe disease — a key secondary endpoint. The company plans to file for emergency use authorization with the FDA in the fourth quarter of 2021. The company is also developing a booster dose of its COVID-19 vaccine.
-
-
Novavax Inc. stock underperforms Wednesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Wednesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Why Novavax is Gaining Ground in COVID-19 Vaccine Race
news.google.com • -
Novavax Inc. stock underperforms Monday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Monday when compared to competitors
news.google.com • -
(NVAX) Trading Report
news.google.com • -
Novavax Inc. stock outperforms competitors on strong trading day
news.google.com • -
Should You Buy Novavax Stock After This Regulatory Win?
news.google.com • -
Should You Buy Novavax Stock After This Regulatory Win?
news.google.com • -
Novavax Inc. stock underperforms Thursday when compared to competitors
news.google.com • -
Why Are Novavax Shares Trading Lower Today?
news.google.com •